QuiO
A digital healthcare company
Monday, September 12, 2016
Embassy Suites, Chesterbrook, Pennsylvania (directions)
|
About
|
QuiO (/ kwee-oh /) is a digital healthcare company that improves clinical trials and disease management through remote monitoring of home injections.
The Smartinjector is the world's first fully-connected drug delivery device, enabling real-time adherence monitoring for self-injected medications. The injection device passively records and wirelessly sends data with no smartphone, WiFi or syncing required. Each Smartinjector device is powered by the Connect Platform, a cloud-based software platform that includes data management, patient monitoring and AI-based support capabilities. The Connect Platform also integrates with 3rd party patient devices, including fitness trackers, weight scales, blood pressure cuffs and glucose meters. For the first time, care providers can see a comprehensive view of their patients' health outside of the clinic. The monitoring and support software ensures providers aren't overwhelmed with incoming data, and delivers real-time automated support to the patient based on clinically-meaningful data points. The solution is affordable to deploy and scalable across different diseases and injectable therapies. Most importantly, it's easy for patients to use, fitting seamlessly into their daily routine.
3 Major Issues
|
- Fundraising: QuiO is currently seeking $2MM in funding to complete product development, run a pilot and achieve 510(k) clearance for the first Smartinjector device. The problem is, most investors are more interested in the next round of financing after regulatory clearance and clinical validation. How can we overcome this chicken and egg problem? What are some strategies or tactics that can help successfully close this first round prior to regulatory clearance and pilot data? Who is the most likely investor in this round (individuals, angel groups, seed stage VC, strategics)? What are some alternative funding sources that can be leveraged within a realistic timeframe (e.g. not SBIR)?
- Pilot: QuiO intends to run a pilot once the first Smartinjector device is complete (Q1 2017). The plan is currently to sponsor our own study in anemia for chronic kidney disease patients self-injecting epoetin (20-50 patients over 3 month treatment regimen). What amount of costs can be expected in order to successfully run such a pilot? Where should the pilot be sponsored in order to maximize our chance at success (academic medical center vs. hospital vs. dialysis clinic)? Are there any strategies or tactics for securing an external sponsor for the pilot (industry or researcher)?
- Go To Market: Monitoring home injections and improving adherence to injectable therapies benefits pharmaceutical companies and risk-bearing entities (health plans, self-insured employers, integrated delivery networks). However, there is a risk that both pharmaceutical companies and risk-bearing entities look to each other to purchase this technology. What geographies (US vs Europe), customers (pharma vs risk bearer) and therapeutic areas (clinical trials, diabetes, autoimmune, neurology, etc.) are well-positioned today to adopt this technology? What are some market trends that either need to be overcome or can be leveraged in order to drive early sales? What are the sales, revenue and pricing models that complement this technology?
Program:
|
6:30 - Cocktails & Dinner (Cash bar and special 2-entree buffet menu)
8:00 - Alexander Dahmani, co-founder and CEO of QuiO, will deliver the Company's "Elevator" Pitch to the Group
8:20 - A Panel will address three major issues crucial to helping the Company reach the next level.
9:00 - Open discussion: members and guests
|
 |
 Slides
None available at this time
 Audio
None available at this time
 Video
None available at this time
 Webcast
None available at this time
|
|
|
